IMMP
Immutep·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 0
Bearish signal 1
Three Black Crows
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IMMP
Immutep Limited
A biotech company that develops novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease
Biological Technology
05/21/1987
04/16/2012
NASDAQ Stock Exchange
51
06-30
Depository Receipts (Ordinary Shares)
Level 32, Australia Square, 264 George Street, Sydney 2000, New South Wales, Australia
Biotechnology and Medical Research
Immutep Limited, incorporated in Australia on May 21, 1987, is a late-stage biotechnology company focused on the development of novel immunotherapies targeting the lymphocyte activating gene -3 (LAG-3) for the treatment of cancer and autoimmune diseases. As a pioneer in the science of LAG-3, Immutep has built a diverse portfolio of products designed to harness the body's immune system through innovative therapeutic mechanisms. The company's lead clinical candidate, eftilagimod alfa (IMP321), is a first-in-class fusion protein designed to enhance immune activation across various cancer types and is currently being investigated in several global clinical trials. In addition to the field of oncology, Immutep is developing LAG-3 agonists for autoimmune diseases and collaborating with major research institutions and pharmaceutical partners.
Company Financials
EPS
IMMP has released its 2022 Q2 earnings. EPS was reported at -0.02, versus the expected 0, missing expectations. The chart below visualizes how IMMP has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
